Study on Preliminary Safety and Efficacy of the ARC Therapy Using the ARC-IM Lumbar System to Support Mobility in People With Chronic Spinal Cord Injury (BoxSwitch) (BoxSwitch)
Spinal Cord Injuries
About this trial
This is an interventional treatment trial for Spinal Cord Injuries focused on measuring SCI, Spinal Cord Injury, Epidural Spinal Stimulation
Eligibility Criteria
Inclusion Criteria: Having completed the main phase of the STIMO study (NCT02936453) and having improved on at least one of the primary or secondary endpoints (WISCI II Score, 10-Meter Walk test, Weight Bearing Capacity, SCIM III Score or 6-Minute Walk test). Age 18-65 SCI graded as American Spinal Injury Association Impairment Scale (AIS) A, B, C & D SCI ≥ 12months SCI lesion level T10 and above with preservation of conus function SCI due to trauma Stable medical, physical and psychological condition as considered by the investigators Able to understand and interact with the study team in French or English Agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments Must provide and sign the Informed Consent prior to any study-related procedures Exclusion Criteria: Diseases and conditions that would increase the morbidity and mortality of spinal cord injury surgery History of myocardial infarction or cerebrovascular event within the past 6 months Limitation of walking function based on accompanying (CNS) disorders (systemic malignant disorders, cardiovascular disorders restricting physical training, peripheral nerve disorders) Any active implanted cardiac device such as pacemaker or defibrillator Any indication that would require diathermy Any indication that would require MRI Any anatomical limitations in the implantation area as judged by the investigators Other conditions that would make the subject unable to participate in testing in the judgement of the investigators Clinically significant mental illness in the judgement of the investigators Presence of indwelling baclofen or insulin pump Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, or dementia of the participant Enrolment of the investigator, his/her family members, employees, and other dependent persons
Sites / Locations
Arms of the Study
Arm 1
Experimental
Targeted Epidural Spinal Stimulation
Single arm study: the participants that have undergone the STIMO study will be proposed to exchange their currently implanted system with selected components from the ARC-IM Lumbar system. After the surgery, the participants will perform around 20 optimization sessions that may include rehabilitation to configure the neuromodulation system. Then the participants will use the ARC-IM Lumbar system independently during daily life activities until the end of the 36 months post-surgery. Assessments will be planned throughout the course of the study at the end of the optimization phase, after 12 and 24 months post-surgery and at the end of the study, with and/or stimulation.